Difference between revisions of "CD138"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
*[[Plasmacytoid urothelial carcinoma]].<ref name=pmid24246859>{{Cite journal | last1 = Zhang | first1 = W. | last2 = Jiang | first2 = YX. | last3 = Liu | first3 = Y. | last4 = Yu | first4 = WJ. | last5 = Zhao | first5 = H. | last6 = Li | first6 = YJ. | title = [Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases]. | journal = Zhonghua Bing Li Xue Za Zhi | volume = 42 | issue = 7 | pages = 433-7 | month = Jul | year = 2013 | doi = | PMID = 24246859 }}</ref> | *[[Plasmacytoid urothelial carcinoma]].<ref name=pmid24246859>{{Cite journal | last1 = Zhang | first1 = W. | last2 = Jiang | first2 = YX. | last3 = Liu | first3 = Y. | last4 = Yu | first4 = WJ. | last5 = Zhao | first5 = H. | last6 = Li | first6 = YJ. | title = [Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases]. | journal = Zhonghua Bing Li Xue Za Zhi | volume = 42 | issue = 7 | pages = 433-7 | month = Jul | year = 2013 | doi = | PMID = 24246859 }}</ref> | ||
==Variable | |||
*Adenocarcinoma - esp. gastrointestinal tract, female reproductive organs and breast.<ref name=pmid12866374/> | |||
==Negative== | |||
*[[Malignant mesothelioma]].<ref name=pmid12866374>{{Cite journal | last1 = Chu | first1 = PG. | last2 = Arber | first2 = DA. | last3 = Weiss | first3 = LM. | title = Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases. | journal = Am J Clin Pathol | volume = 120 | issue = 1 | pages = 64-70 | month = Jul | year = 2003 | doi = 10.1309/48KC-17WA-U69B-TBXQ | PMID = 12866374 }}</ref> | |||
==See also== | ==See also== | ||
*[[Plasma cell]]. | *[[Plasma cell]]. | ||
Revision as of 15:10, 9 August 2016
CD138, also known as Syndecan-1 (abbreviated SDC1),[1] is an immunostain that marks plasma cells.
It plays a role in angiogenesis and cellular proliferation.[2]
Positive
- Plasma cells.[3]
- Plasma cell neoplasm.
- Triple negative breast cancer.[4]
- Plasmacytoid urothelial carcinoma.[5]
==Variable
- Adenocarcinoma - esp. gastrointestinal tract, female reproductive organs and breast.[6]
Negative
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 186355
- ↑ Guo, Q.; Yang, X.; Ma, Y.; Ma, L. (2015). "Syndecan-1 serves as a marker for the progression of epithelial ovarian carcinoma.". Eur J Gynaecol Oncol 36 (5): 506-13. PMID 26513873.
- ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 554. ISBN 978-0781765275.
- ↑ Lim, GH.; Tan, PH.; Jara-Lazaro, AR.; Thike, AA.; Sim, WC.; Yap, VB.; Yip, GW. (Sep 2014). "Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival.". Singapore Med J 55 (9): 468-72. PMID 25273930.
- ↑ Zhang, W.; Jiang, YX.; Liu, Y.; Yu, WJ.; Zhao, H.; Li, YJ. (Jul 2013). "[Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic study of 16 cases].". Zhonghua Bing Li Xue Za Zhi 42 (7): 433-7. PMID 24246859.
- ↑ 6.0 6.1 Chu, PG.; Arber, DA.; Weiss, LM. (Jul 2003). "Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases.". Am J Clin Pathol 120 (1): 64-70. doi:10.1309/48KC-17WA-U69B-TBXQ. PMID 12866374.
.